ATRA240517C1500
- 0.05
- 0.000.00%
Atara Biotherapeutics Newsroom
H.C. Wainwright Maintains Atara Biotherapeutics(ATRA.US) With Hold Rating
H.C. Wainwright analyst Robert Burns maintains $Atara Biotherapeutics(ATRA.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 24.0% and a total average return of -22
Express News | Adiumentum Capital Fund I LP Reports 6.7% Stake in Atara Biotherapeutics as of May 15- SEC Filing
Express News | Adiumentum Capital Fund I LP: To Engage in Talks With Atara Biotherapeutics to Discuss Business, Financial Condition, Strategic Plans, Governance
Express News | Adiumentum Capital Fund I LP Says Acquired Beneficial Ownership of Atara Biotherapeutics Common Stock Shares in Belief Stock Was Undervalued
This Insider Has Just Sold Shares In Atara Biotherapeutics
We note that the Atara Biotherapeutics, Inc. (NASDAQ:ATRA) President, Pascal Touchon, recently sold US$50k worth of stock for US$0.62 per share. It might not be a huge sale, but it did reduce their
HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeutics
HC Wainwright & Co. analyst Robert Burns reiterates Atara Biotherapeutics (NASDAQ:ATRA) with a Neutral.
Atara Biotherapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/22/2024 — HC Wainwright & Co. Reiterates → Neutral 04/01/2024 249.7% Stifel $4.8 → $2.3 Maintains Hold
Atara Biotherapeutics: A Balanced Hold Amidst FDA Approval Prospects and Valuation Uncertainties
Les Laboratoires Pierre Fabre Annoncent La Soumission Par Atara Biotherapeutics D'une Demande De Licence Biologique De Tabelecleucel (Tab-cel) Pour Le Traitement De La Maladie Lymphoproliférative Post-transplantation Et Positive Au Virus...
Les Laboratoires Pierre Fabre Annoncent La Soumission Par Atara Biotherapeutics D'une Demande De Licence Biologique De Tabelecleucel (Tab-cel) Pour Le Traitement De La Maladie Lymphoproliférative Pos
Pierre Fabre Laboratories Announces the Submission by Atara Biotherapeutics of Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease With U.S FDA
Pierre Fabre Laboratories today announce the submission by Atara Biotherapeutics (ATARA), a leader in T-cell immunotherapies, of Tabelecleucel...
Sector Update: Health Care Stocks Ease Monday Afternoon
Health care stocks were lower Monday afternoon with the NYSE Health Care Index fractionally lower and the Health Care Select Sector SPDR Fund (XLV) down 0.1%. The iShares Biotechnology ETF (IBB) rose
Atara Biotherapeutics Files Biologics License Application for Tabelecleucel With FDA; Shares Rise
Atara Biotherapeutics (ATRA) said Monday it has filed a biologics license application with the US Food and Drug Administration for tabelecleucel, or tab-cel, to treat patients with Epstein-Barr virus positive post-transplant lymphoproliferative disease.
Express News | Atara Eligible for Additional $60M Upon FDA Approval
Express News | Atara Biotherapeutics Inc - Acceptance of Bla Will Trigger $20 Mln Milestone Payment From Pierre Fabre Laboratories
Express News | Atara Biotherapeutics Submits Tabelecleucel (Tab-Cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease With U.S. FDA
Analysts Have Conflicting Sentiments on These Healthcare Companies: Deciphera Pharmaceuticals (DCPH), Atara Biotherapeutics (ATRA) and Nkarta (NKTX)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cytek Biosciences (CTKB), Elanco Animal Health (ELAN) and Atara Biotherapeutics (ATRA)
Atara Biotherapeutics First Quarter 2024 Earnings: Beats Expectations
Buy Rating Affirmed for Atara Biotherapeutics on Strong Pipeline and Financial Health
Atara Biotherapeutics | 10-Q: Quarterly report